Pulmonary Sarcoidosis

Mihailović-Vučinić, Violeta; Jovanović, Dragana

doi:10.1016/j.ccm.2008.03.002

Cited by 43 publications

(45 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the introduction of CT scan, especially high-resolution CT, awareness of pleural manifestations of sarcoidosis has increased, allowing detection of more subtle cases of pleural involvement, a rare (with 2-4% frequency) but significant involvement (18). The rates were similar in the present study, however, pleural calsification reported among the CT findings was conspicuous.…”

supporting

confidence: 69%

Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis)

Kıter

Müsellim²,

Çetınkaya³

et al. 2011

Tuberk Toraks

View full text Add to dashboard Cite

supporting

confidence: 69%

Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis)

Kıter

Müsellim²,

Çetınkaya³

et al. 2011

Tuberk Toraks

View full text Add to dashboard Cite

“…Radiologic data showed that 14 patients had stage IV sarcoidosis, 24 patients had stage III sarcoidosis, 28 patients had stage II sarcoidosis, 17 patients had stage I sarcoidosis, and 9 patients had stage 0 sarcoidosis. 10 Prevalence of Pneumothorax LAM: Pneumothorax was diagnosed in 16 patients, 5 by chest roentgenograms and 11 by CT scans only. Of the 16 patients in whom pneumothorax was diagnosed, 14 had traveled by airplane and 2 by ground transportation.…”

Section: Mode Of Travelmentioning

confidence: 99%

Pneumothorax After Air Travel in Lymphangioleiomyomatosis, Idiopathic Pulmonary Fibrosis, and Sarcoidosis

Taveira-DaSilva

Burstein

Hathaway

et al. 2009

Chest

View full text Add to dashboard Cite

Background:The prevalence of pneumothorax associated with travel in patients with interstitial lung diseases is unknown. In patients with lymphangioleiomyomatosis (LAM), in whom pneumothorax is common, patients are often concerned about the occurrence of a life-threatening event during air travel. The aim of this study was to determine the prevalence of pneumothorax associated with air travel in patients with LAM, idiopathic pulmonary fibrosis (IPF), and sarcoidosis.

show abstract

“…Sarcoidosis is diagnosed by clinical findings and corroborating histological evidence of non-caseating epithelioid cell granulomas [2]. Over 90% of patients have lung involvement [3], while skin lesions are observed in ,25% of patients [4]. Although spontaneous remissions occur in almost two-thirds of patients, chronic or progressive disease is seen in 10-30% [5], with permanent pulmonary or extrapulmonary sequelae in at least 10-20% of patients.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

et al. 2014

View full text Add to dashboard Cite

Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-a. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-a, respectively.Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo. Patients underwent corticosteroid tapering between weeks 16 and 28. The primary end-point was week 16 change in percentage predicted forced vital capacity (DFVC % pred) in the lung group. Major secondary end-points were: week 28 for DFVC % pred, 6-min walking distance, St George's Respiratory Questionnaire (lung group), and Skin Physician Global Assessment response (skin group).At week 16, no significant differences were observed in DFVC % pred with ustekinumab (-0.15, p50.13) or golimumab (1.15, p50.54) compared with placebo (2.02). At week 28, there were no significant improvements in the major secondary end-points, although a nonsignificant numerically greater Skin Physician Global Assessment response was observed following golimumab treatment (53%) when compared with the placebo (30%). Serious adverse events were similar in all treatment groups.Although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. However, trends towards improvement were observed with golimumab in some dermatological end-points. @ERSpublicationsNeither ustekinumab nor golimumab demonstrated efficacy for the treatment of patients with pulmonary sarcoidosis

show abstract

Pulmonary Sarcoidosis

Cited by 43 publications

References 95 publications

Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis)

Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis)

Pneumothorax After Air Travel in Lymphangioleiomyomatosis, Idiopathic Pulmonary Fibrosis, and Sarcoidosis

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis

Contact Info

Product

Resources

About